Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.

Authors

Mehdi Hamadani

Mehdi Hamadani

Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Mehdi Hamadani , Yuliya Linhares , Mitul Gandhi , Michael Chung , Helena Adamis , David Ungar , Carmelo Carlo-Stella

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04384484

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS7574)

DOI

10.1200/JCO.2021.39.15_suppl.TPS7574

Abstract #

TPS7574

Poster Bd #

Online Only

Abstract Disclosures